Tortoise Investment Management LLC Has $49,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Tortoise Investment Management LLC boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 77.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 263 shares of the medical research company’s stock after purchasing an additional 115 shares during the period. Tortoise Investment Management LLC’s holdings in Charles River Laboratories International were worth $49,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Empirical Finance LLC raised its stake in Charles River Laboratories International by 4.2% in the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after buying an additional 53 shares during the period. Fiduciary Financial Group LLC raised its stake in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after acquiring an additional 63 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. M&T Bank Corp boosted its position in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock worth $394,000 after purchasing an additional 66 shares during the period. Finally, Cornerstone Investment Partners LLC increased its holdings in shares of Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after purchasing an additional 69 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO James C. Foster bought 6,075 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Down 4.9 %

Shares of NYSE CRL opened at $166.53 on Wednesday. The stock has a market capitalization of $8.52 billion, a P/E ratio of 1,110.23, a PEG ratio of 4.54 and a beta of 1.45. The stock’s fifty day moving average is $168.63 and its 200 day moving average is $185.18. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $274.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business’s quarterly revenue was down 1.1% compared to the same quarter last year. During the same period last year, the firm earned $2.46 EPS. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Robert W. Baird cut their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Bank of America reduced their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Morgan Stanley lowered their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. Finally, William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $198.36.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).